Yan-Wen Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yan-Wen Jin has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Fu-Yu Li
Division of Biliary Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China
22 shared publications Hai-Jie Hu
Division of Biliary Tract Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
6 shared publications- Hai-Jie Hu
Division of Biliary Tract Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China
6 shared publications Wen-Jie Ma
Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu, China
6 shared publicationsFei Liu
Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu, China
5 shared publicationsTian-Run Lv
Department of Biliary Tract Surgery, General Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
5 shared publications
Latest Publications
- 6 May 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (7) , 111869
Hepatocellular carcinoma in the immunotherapy Era: A SEER-based era comparison across the U.S. FDA transition
- 6 May 2026
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (7) , 111869
Hepatocellular carcinoma in the immunotherapy Era: A SEER-based era comparison across the U.S. FDA transition
- Open Access
- 24 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (43) , e45491
Unveiling causal links between serum amino acid levels and risk of hepatobiliary neoplasms by Mendelian randomization study
The causal links between serum amino acids (AAs) and hepatobiliary neoplasms remain unclear. This study aimed to systematically investigate these associations using Mendelian randomization (MR). Summary-level data on 20 serum AAs were obtained from publicly available genome-wide association studies. Genome-wide association studies data on hepatobiliary neoplasms – including primary liver cancer (PLC), hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), gallbladder and extrahepatic bile duct carcinoma, secondary liver cancer, benign liver tumors, and benign tumors of the extrahepatic bile ducts – were derived from FinnGen and 2 UK Biobank-based studies. A meta-analysis was conducted to calculate pooled effect sizes. Inverse variance weighting was the primary method, supplemented by MR-Egger, weighted median, MR.RAPS, maximum likelihood, and MR-PRESSO methods for sensitive analyses. Higher serum methionine was associated with lower risks of PLC (OR = 0.84, 95% CI: 0.72–0.97, P = .021) and HCC (OR = 0.87, 95% CI: 0.80–0.94, P < .001), but not ICC. Alanine increased PLC risk (OR = 1.19, 95% CI: 1.00–1.42, P = .047), with no significant effect on HCC or ICC. No AAs were linked to gallbladder and extrahepatic bile duct carcinoma or secondary liver cancer. For benign tumors, aspartate (OR = 1.13, 95% CI: 1.01–1.26, P = .037), cysteine (OR = 0.72, 95% CI: 0.57–0.92, P = .008), and lysine (OR = 1.49, 95% CI: 1.15–1.93, P = .003) were significantly associated with benign liver tumors or benign tumors of the extrahepatic bile ducts. This study offers robust evidence of causal associations between specific serum AAs and hepatobiliary neoplasms, emphasizing their potential as biomarkers and modifiable targets for early intervention.
- 24 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (43) , e45491
Open AccessUnveiling causal links between serum amino acid levels and risk of hepatobiliary neoplasms by Mendelian randomization study
The causal links between serum amino acids (AAs) and hepatobiliary neoplasms remain unclear. This study aimed to systematically investigate these associations using Mendelian randomization (MR). Summary-level data on 20 serum AAs were obtained from publicly available genome-wide association studies. Genome-wide association studies data on hepatobiliary neoplasms – including primary liver cancer (PLC), hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), gallbladder and extrahepatic bile duct carcinoma, secondary liver cancer, benign liver tumors, and benign tumors of the extrahepatic bile ducts – were derived from FinnGen and 2 UK Biobank-based studies. A meta-analysis was conducted to calculate pooled effect sizes. Inverse variance weighting was the primary method, supplemented by MR-Egger, weighted median, MR.RAPS, maximum likelihood, and MR-PRESSO methods for sensitive analyses. Higher serum methionine was associated with lower risks of PLC (OR = 0.84, 95% CI: 0.72–0.97, P = .021) and HCC (OR = 0.87, 95% CI: 0.80–0.94, P < .001), but not ICC. Alanine increased PLC risk (OR = 1.19, 95% CI: 1.00–1.42, P = .047), with no significant effect on HCC or ICC. No AAs were linked to gallbladder and extrahepatic bile duct carcinoma or secondary liver cancer. For benign tumors, aspartate (OR = 1.13, 95% CI: 1.01–1.26, P = .037), cysteine (OR = 0.72, 95% CI: 0.57–0.92, P = .008), and lysine (OR = 1.49, 95% CI: 1.15–1.93, P = .003) were significantly associated with benign liver tumors or benign tumors of the extrahepatic bile ducts. This study offers robust evidence of causal associations between specific serum AAs and hepatobiliary neoplasms, emphasizing their potential as biomarkers and modifiable targets for early intervention.
- Open Access
- 26 May 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (8) , 5475-5484
Preoperative biliary drainage for patients with malignant obstructive jaundice: an update on the systematic review and model-based Bayesian network meta-analysis
Background: Several procedures are available for preoperative biliary drainage, but the necessity and best clinical choice remain uncertain. The purpose was to compare the efficacy and safety of seven methods of preoperative biliary drainage with different surgical procedures, materials, or places of stents in patients with malignant obstructive jaundice. Methods: This study included randomized controlled trials, prospective and retrospective trials, and case-control studies focusing on preoperative biliary drainage (PBD). Meta-analysis and Bayesian Model-Based Network Meta-Analysis were used for data synthesis. The results were reported as odds ratios with 95% confidence intervals for binary outcomes and mean differences or standardized mean differences with 95% confidence intervals for continuous outcomes. Results: This study included 81 articles involving 26 251 patients. Fully covered self-expandable metal stents with endoscopic retrograde cholangiopancreatography have the fewest adverse events compared with plastic stents (OR = 0.16, 95% CI = 0.05 to 0.41, moderate certainty) and other procedures, yet associated with the highest incidence of pancreatitis. Plastic stent was associated with increased complications and shorter duration. Internal stent is the best for patients with perihilar obstruction. Conclusions: This study suggests that preoperative biliary drainage exerts significant variation in clinical efficacy and safety across different procedures. Fully covered self-expandable metal stents was the most recommended, while plastic stent is not recommended. Endoscopic retrograde cholangiopancreatography is the preferred procedure for preoperative biliary drainage, with percutaneous biliary drainage serving as a viable alternative. Internal stent is the most recommended for patients with perihilar obstruction.
- 26 May 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (8) , 5475-5484
Open AccessPreoperative biliary drainage for patients with malignant obstructive jaundice: an update on the systematic review and model-based Bayesian network meta-analysis
Background: Several procedures are available for preoperative biliary drainage, but the necessity and best clinical choice remain uncertain. The purpose was to compare the efficacy and safety of seven methods of preoperative biliary drainage with different surgical procedures, materials, or places of stents in patients with malignant obstructive jaundice. Methods: This study included randomized controlled trials, prospective and retrospective trials, and case-control studies focusing on preoperative biliary drainage (PBD). Meta-analysis and Bayesian Model-Based Network Meta-Analysis were used for data synthesis. The results were reported as odds ratios with 95% confidence intervals for binary outcomes and mean differences or standardized mean differences with 95% confidence intervals for continuous outcomes. Results: This study included 81 articles involving 26 251 patients. Fully covered self-expandable metal stents with endoscopic retrograde cholangiopancreatography have the fewest adverse events compared with plastic stents (OR = 0.16, 95% CI = 0.05 to 0.41, moderate certainty) and other procedures, yet associated with the highest incidence of pancreatitis. Plastic stent was associated with increased complications and shorter duration. Internal stent is the best for patients with perihilar obstruction. Conclusions: This study suggests that preoperative biliary drainage exerts significant variation in clinical efficacy and safety across different procedures. Fully covered self-expandable metal stents was the most recommended, while plastic stent is not recommended. Endoscopic retrograde cholangiopancreatography is the preferred procedure for preoperative biliary drainage, with percutaneous biliary drainage serving as a viable alternative. Internal stent is the most recommended for patients with perihilar obstruction.
- Open Access
- 10 August 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (10) , 4519-4521
Self-expandable metal versus plastic stents for malignant biliary obstruction
- 10 August 2024
- Published by Elsevier in Asian Journal of Surgery
- Vol. 47 (10) , 4519-4521
Open AccessSelf-expandable metal versus plastic stents for malignant biliary obstruction
- Open Access
- 22 July 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1217250
Does the size of the neuroendocrine-carcinoma component determine the prognosis of gallbladder cancer?
Background: Gallbladder mixed neuroendocrine-non-neuroendocrine neoplasm generally consists of a gallbladder neuroendocrine tumor and a non-neuroendocrine component. The World Health Organization (WHO) in 2019 established a guideline requiring each component, both neuroendocrine and non-neuroendocrine, to account for a minimum of 30% of the tumor mass.Methods: Patients after surgery resection and diagnosed at microscopy evaluation with pure gallbladder neuroendocrine carcinoma (GBNEC), gallbladder mixed adeno-neuroendocrine carcinoma (GBMANEC, GBNEC≥30%), and gallbladder carcinoma mixed with a small fraction of GBNEC (GBNEC 8th edition). The majority of included patients (79.17%) underwent curative surgical resection (R0), with only ten patients having tumoral resection margins. In the analysis comparing patients with GBNEC percentage (GBNEC≥30% vs. GBNEC<30%), the basic demographics and tumor characteristics of most patients were comparable. The prognosis of these patients was also comparable, with a median OS of 23.65 months versus 20.40 months (P=0.13) and a median RFS of 17.1 months versus 12.3 months (P=0.24). However, patients with GBADC or GBSCC mixed with GBNEC <30% had a statistically significant decreased OS and RFS (both P<0.0001)) compared with GBNEC and GBMANEC. Patients with GBNEC who exhibited advanced tumor stages and lymphovascular invasion had a higher risk of experiencing worse overall survival (OS) and recurrence-free survival (RFS). However, a 30% GBNEC component was not identified as an independent risk factor.Conclusion: Patients with GBNEC were frequently diagnosed at advanced stages and their prognosis is poor. The 30% percentage of the GBNEC component is not related to the patient’s survival.
- 22 July 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1217250
Open AccessDoes the size of the neuroendocrine-carcinoma component determine the prognosis of gallbladder cancer?
Background: Gallbladder mixed neuroendocrine-non-neuroendocrine neoplasm generally consists of a gallbladder neuroendocrine tumor and a non-neuroendocrine component. The World Health Organization (WHO) in 2019 established a guideline requiring each component, both neuroendocrine and non-neuroendocrine, to account for a minimum of 30% of the tumor mass.Methods: Patients after surgery resection and diagnosed at microscopy evaluation with pure gallbladder neuroendocrine carcinoma (GBNEC), gallbladder mixed adeno-neuroendocrine carcinoma (GBMANEC, GBNEC≥30%), and gallbladder carcinoma mixed with a small fraction of GBNEC (GBNEC 8th edition). The majority of included patients (79.17%) underwent curative surgical resection (R0), with only ten patients having tumoral resection margins. In the analysis comparing patients with GBNEC percentage (GBNEC≥30% vs. GBNEC<30%), the basic demographics and tumor characteristics of most patients were comparable. The prognosis of these patients was also comparable, with a median OS of 23.65 months versus 20.40 months (P=0.13) and a median RFS of 17.1 months versus 12.3 months (P=0.24). However, patients with GBADC or GBSCC mixed with GBNEC <30% had a statistically significant decreased OS and RFS (both P<0.0001)) compared with GBNEC and GBMANEC. Patients with GBNEC who exhibited advanced tumor stages and lymphovascular invasion had a higher risk of experiencing worse overall survival (OS) and recurrence-free survival (RFS). However, a 30% GBNEC component was not identified as an independent risk factor.Conclusion: Patients with GBNEC were frequently diagnosed at advanced stages and their prognosis is poor. The 30% percentage of the GBNEC component is not related to the patient’s survival.
- 4 March 2024
- Published by Springer Nature in Updates in Surgery
- Vol. 76 (4) , 1235-1245
The prognostic value of combined preoperative PLR and CA19-9 in patients with resectable gallbladder cancer
The platelet to lymphocyte ratio (PLR) is the marker of host inflammation and it is a potential significant prognostic indicator in various different tumors. The serum carbohydrate antigen 19–9 (CA19-9) is a tumor-associated antigen and it is associated with poor prognosis of gallbladder cancer (GBC). We aimed to analyze the prognostic value of the combination of preoperative PLR and CA19-9 in patients with GBC. A total of 287 GBC patients who underwent curative surgery in our institution was included. To analyze the relationship between PLR and CA19-9 and clinicopathological features. A receiver operating characteristic (ROC) curve was used to identify the optimal cutoff value for PLR and CA19-9. The Kaplan–Meier method was used to estimate the overall survival (OS). Meanwhile, the univariate and multivariate Cox regression models were used to assess the risk factors for OS. The cutoff values of 146.82 and 36.32U/ml defined as high PLR and high CA19-9, respectively. Furthermore, survival analysis showed that patients with PLR > 146.82 and CA19-9 > 36.32 U/ml had a worse prognosis than patients with PLR ≤ 146.82 and CA19-9 ≤ 36.32 U/ml, respectively. The multivariate analysis demonstrated that PLR (hazard ratio (HR) = 1.863, 95% CI: 1.366–2.542, P < 0.001) and CA19-9 (HR = 1.412, 95% CI: 1.021–1.952, P = 0.037) were independent prognostic factors in the GBC patients. When we combined these two parameters, the area under the ROC curve increased from 0.624 (PLR) and 0.661 (CA19-9) to 0.711. In addition, the 1-, 3-, and 5-year OS of group A (patients with PLR ≤ 146.82 and CA19-9 ≤ 36.32 U/ml), group B (patients with either of PLR > 146.82 or CA19-9 > 36.32 U/ml) and group C (patients with PLR > 146.82 and CA19-9 > 36.32 U/ml) were 83.6%, 58.6%, 22.5%, 52.4%, 19.5%, 11.5%, and 42.3%, 11.9%, 0%, respectively. The preoperative PLR and serum CA19-9 are associated with prognosis of patients with GBC. The combination of PLR and CA19-9 may serve as a significant prognostic biomarker for GBC patients superior to either PLR or CA19-9 alone.
- 4 March 2024
- Published by Springer Nature in Updates in Surgery
- Vol. 76 (4) , 1235-1245
The prognostic value of combined preoperative PLR and CA19-9 in patients with resectable gallbladder cancer
The platelet to lymphocyte ratio (PLR) is the marker of host inflammation and it is a potential significant prognostic indicator in various different tumors. The serum carbohydrate antigen 19–9 (CA19-9) is a tumor-associated antigen and it is associated with poor prognosis of gallbladder cancer (GBC). We aimed to analyze the prognostic value of the combination of preoperative PLR and CA19-9 in patients with GBC. A total of 287 GBC patients who underwent curative surgery in our institution was included. To analyze the relationship between PLR and CA19-9 and clinicopathological features. A receiver operating characteristic (ROC) curve was used to identify the optimal cutoff value for PLR and CA19-9. The Kaplan–Meier method was used to estimate the overall survival (OS). Meanwhile, the univariate and multivariate Cox regression models were used to assess the risk factors for OS. The cutoff values of 146.82 and 36.32U/ml defined as high PLR and high CA19-9, respectively. Furthermore, survival analysis showed that patients with PLR > 146.82 and CA19-9 > 36.32 U/ml had a worse prognosis than patients with PLR ≤ 146.82 and CA19-9 ≤ 36.32 U/ml, respectively. The multivariate analysis demonstrated that PLR (hazard ratio (HR) = 1.863, 95% CI: 1.366–2.542, P < 0.001) and CA19-9 (HR = 1.412, 95% CI: 1.021–1.952, P = 0.037) were independent prognostic factors in the GBC patients. When we combined these two parameters, the area under the ROC curve increased from 0.624 (PLR) and 0.661 (CA19-9) to 0.711. In addition, the 1-, 3-, and 5-year OS of group A (patients with PLR ≤ 146.82 and CA19-9 ≤ 36.32 U/ml), group B (patients with either of PLR > 146.82 or CA19-9 > 36.32 U/ml) and group C (patients with PLR > 146.82 and CA19-9 > 36.32 U/ml) were 83.6%, 58.6%, 22.5%, 52.4%, 19.5%, 11.5%, and 42.3%, 11.9%, 0%, respectively. The preoperative PLR and serum CA19-9 are associated with prognosis of patients with GBC. The combination of PLR and CA19-9 may serve as a significant prognostic biomarker for GBC patients superior to either PLR or CA19-9 alone.
- 2 February 2024
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 409 (1) , 1-11
Prognostic value of combined preoperative inflammatory marker neutrophil–lymphocyte ratio and platelet distribution width in patients with gallbladder carcinoma
Background The neutrophil–lymphocyte ratio (NLR) and platelet distribution width (PDW) are associated with poor prognosis in various cancers. We aimed to analyze the prognostic value of the combination of preoperative NLR and PDW in patients with gallbladder carcinoma (GBC). Methods A total of 287 GBC patients who underwent curative-intent surgery in our institution was included. The relationship between NLR and PDW and clinicopathological features were analyzed. The receiver operating characteristic (ROC) curves were used to determine the optimal cutoff value for NLR and PDW. Overall survival (OS) was estimated using the Kaplan–Meier method. Meanwhile, the univariate and multivariate Cox regression models were used to assess the risk factors for OS. Results The optimal cutoff value of NLR and PDW was 3.00 and 14.76, respectively. In addition, survival analysis demonstrated that patients with NLR > 3.00 and PDW > 14.76 had a worse prognosis than patients with NLR ≤ 3.00 and PDW ≤ 14.76, respectively. The multivariate analysis showed that NLR and PDW were independent prognostic factors in the patients with GBC. When we combined NLR and PDW, the area under the ROC curve increased from 0.665 (NLR) and 0.632 (PDW) to 0.676. Moreover, the 1-, 3-, and 5-year OS of group A (patients with NLR ≤ 3.00 and PDW ≤ 14.76), group B (patients with either of NLR > 3.00 or PDW > 14.76) and group C (patients with NLR > 3.00 and PDW > 14.76) were 88.7%, 62.6%, 28.1%, 65.1%, 26.9%, 13.1%, and 34.8%, 8.3%, 0%, respectively. Conclusion The combination of NLR and PDW may serve as a significant prognostic biomarker for GBC patients superior to either NLR or PDW alone.
- 2 February 2024
- Published by Springer Nature in Langenbeck's Archives of Surgery
- Vol. 409 (1) , 1-11
Prognostic value of combined preoperative inflammatory marker neutrophil–lymphocyte ratio and platelet distribution width in patients with gallbladder carcinoma
Background The neutrophil–lymphocyte ratio (NLR) and platelet distribution width (PDW) are associated with poor prognosis in various cancers. We aimed to analyze the prognostic value of the combination of preoperative NLR and PDW in patients with gallbladder carcinoma (GBC). Methods A total of 287 GBC patients who underwent curative-intent surgery in our institution was included. The relationship between NLR and PDW and clinicopathological features were analyzed. The receiver operating characteristic (ROC) curves were used to determine the optimal cutoff value for NLR and PDW. Overall survival (OS) was estimated using the Kaplan–Meier method. Meanwhile, the univariate and multivariate Cox regression models were used to assess the risk factors for OS. Results The optimal cutoff value of NLR and PDW was 3.00 and 14.76, respectively. In addition, survival analysis demonstrated that patients with NLR > 3.00 and PDW > 14.76 had a worse prognosis than patients with NLR ≤ 3.00 and PDW ≤ 14.76, respectively. The multivariate analysis showed that NLR and PDW were independent prognostic factors in the patients with GBC. When we combined NLR and PDW, the area under the ROC curve increased from 0.665 (NLR) and 0.632 (PDW) to 0.676. Moreover, the 1-, 3-, and 5-year OS of group A (patients with NLR ≤ 3.00 and PDW ≤ 14.76), group B (patients with either of NLR > 3.00 or PDW > 14.76) and group C (patients with NLR > 3.00 and PDW > 14.76) were 88.7%, 62.6%, 28.1%, 65.1%, 26.9%, 13.1%, and 34.8%, 8.3%, 0%, respectively. Conclusion The combination of NLR and PDW may serve as a significant prognostic biomarker for GBC patients superior to either NLR or PDW alone.
- 30 January 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (5) , 3104-3105
ASO Author Reflections: Laparoscopic Surgery for Intrahepatic Cholangiocarcinoma—Opportunities and Challenges
- 30 January 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (5) , 3104-3105
ASO Author Reflections: Laparoscopic Surgery for Intrahepatic Cholangiocarcinoma—Opportunities and Challenges